Physical functioning in boys with hemophilia in the U.S
- PMID: 22099359
- DOI: 10.1016/j.amepre.2011.09.017
Physical functioning in boys with hemophilia in the U.S
Abstract
Background: Hemophilia is the most common inherited severe bleeding disorder. Although the most frequent complication of repeated hemorrhages is a crippling joint disease that begins in childhood, the extent of resultant joint functional impairment varies widely within the hemophilia population.
Purpose: The goal of this exploratory analysis was to examine a national database that collects information on boys with hemophilia, an X-linked severe congenital bleeding disorder, to determine characteristics associated with increased risk of developing limitations in physical functioning as an outcome of recurrent hemorrhages.
Methods: A standard set of data is collected annually at ∼130 U.S. comprehensive hemophilia treatment centers (HTCs) in a voluntary surveillance program called the Universal Data Collection (UDC) program. Fifteen potential predictors for poor outcomes of physical functioning related to bleeding were examined for boys (aged ≤ 18 years) from 1998 to 2008. Bivariate and multivariate analyses of these predictors performed in 2009 examined associations with self-reported limitation of activities, absenteeism from work or school, and reliance on assistive devices for ambulation and mobility.
Results: Multiple characteristics of underlying hemophilia severity and disease chronicity (in particular, increasing age, presence of joint bleeding, and inhibitor antibodies) were independently associated with increased risk of limitations of physical function. Nonwhite race/ethnicity was associated with each of the poorer functional outcomes in bivariate analyses. After controlling for the potential confounding effects of the multiple population characteristics on race, only African-American race was independently associated with activity restrictions, and African-American and Asian/Pacific Island ethnicity with absenteeism. With the exception of indicators of underlying disease severity, only obesity and medical insurance coverage with Medicaid rather than commercial insurance were independently associated with multiple poor outcomes.
Conclusions: Interventions focused on eliminating inhibitors, improving outcomes for African-American children with hemophilia, and maintaining healthy body weight are warranted. In addition, strategies are needed to assure adequate insurance coverage for all people with hemophilia to eliminate economic barriers to optimal functional outcomes.
Copyright © 2011 American Journal of Preventive Medicine. All rights reserved.
Similar articles
-
Insurance, home therapy, and prophylaxis in U.S. youth with severe hemophilia.Am J Prev Med. 2011 Dec;41(6 Suppl 4):S338-45. doi: 10.1016/j.amepre.2011.09.002. Am J Prev Med. 2011. PMID: 22099356
-
Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.Pediatrics. 2005 Feb;115(2):e173-82. doi: 10.1542/peds.2004-1693. Epub 2005 Jan 3. Pediatrics. 2005. PMID: 15629958
-
Self-reported barriers to hemophilia care in people with factor VIII deficiency.Am J Prev Med. 2011 Dec;41(6 Suppl 4):S346-53. doi: 10.1016/j.amepre.2011.09.003. Am J Prev Med. 2011. PMID: 22099357
-
Reducing obesity and related chronic disease risk in children and youth: a synthesis of evidence with 'best practice' recommendations.Obes Rev. 2006 Feb;7 Suppl 1:7-66. doi: 10.1111/j.1467-789X.2006.00242.x. Obes Rev. 2006. PMID: 16371076 Review.
-
Hemophilia and von Willebrand's disease: 1. Diagnosis, comprehensive care and assessment. Association of Hemophilia Clinic Directors of Canada.CMAJ. 1995 Jul 1;153(1):19-25. CMAJ. 1995. PMID: 7796372 Free PMC article. Review.
Cited by
-
Racial and Ethnic Differences in Distress, Depression, and Quality of Life in people with hemophilia.J Racial Ethn Health Disparities. 2024 Jun;11(3):1394-1404. doi: 10.1007/s40615-023-01616-3. Epub 2023 May 3. J Racial Ethn Health Disparities. 2024. PMID: 37133726
-
Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia.Eur J Health Econ. 2021 Jun;22(4):547-557. doi: 10.1007/s10198-021-01273-5. Epub 2021 Mar 24. Eur J Health Econ. 2021. PMID: 33761029
-
Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.Thromb Haemost. 2020 Oct;120(10):1357-1370. doi: 10.1055/s-0040-1714279. Epub 2020 Jul 27. Thromb Haemost. 2020. PMID: 32717759 Free PMC article. Review.
-
Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.Drug Des Devel Ther. 2020 Feb 3;14:469-481. doi: 10.2147/DDDT.S167731. eCollection 2020. Drug Des Devel Ther. 2020. PMID: 32099331 Free PMC article. Review.
-
Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations.J Blood Med. 2019 Jul 2;10:171-181. doi: 10.2147/JBM.S175952. eCollection 2019. J Blood Med. 2019. PMID: 31308776 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
